Given that Tideglusib have shown good safety and tolerability in patients suffering from different neurological diseases, it is proposed that the repositioning of this in-house designed GSK-3β inhibitor could be a valid therapeutic strategy for the treatment of ALS and other TDP-43 proteinopathies. This evidence concerns the gene TARDBP and proteostasis deficiencies.